缩写名/全名 |
J CLIN ONCOL
JOURNAL OF CLINICAL ONCOLOGY |
||||||||||||||||||||
ISSN号 | 0732-183X | ||||||||||||||||||||
研究方向 | 医学-肿瘤学 | ||||||||||||||||||||
影响因子 | 2015:20.982, 2016:24.008, 2017:26.303, 2018:28.245, 2019:32.956, | ||||||||||||||||||||
出版国家 | UNITED STATES | ||||||||||||||||||||
出版周期 | Biweekly | ||||||||||||||||||||
年文章数 | 285 | ||||||||||||||||||||
出版年份 | 1983 | ||||||||||||||||||||
是否OA | No | ||||||||||||||||||||
审稿周期(仅供参考) | 平均2月 |
||||||||||||||||||||
录用比例 | 约20% | ||||||||||||||||||||
投稿链接 | |||||||||||||||||||||
投稿官网 | http://jco.ascopubs.org/ | ||||||||||||||||||||
h-index | 494 | ||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | ||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial. Author: Jiang J1, Li Y1, Shen Q1,2, Rong X1, Huang X1, Li H1, Zhou L3, Mai HQ4, Zheng D5, Chen MY4, Xu Y1, Li J4, Hui X6, Simone CB 2nd7, Gaertner J8, Argyriou AA9, Chow E10, Chen P3, Tang Y1. Journal: J Clin Oncol. 2019 Jan 10;37(2):135-143. doi: 10.1200/JCO.18.00896. Epub 2018 Nov 20. PubMed DOI |
2. | PHOENIX-GC Trial: Underpowered for Significant Results? Author: Li Z1, Xue K1, Ying X1, Ji J1. Journal: J Clin Oncol. 2019 Jan 10;37(2):167. doi: 10.1200/JCO.18.00364. Epub 2018 Nov 26. PubMed DOI |
3. | Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet! Author: Liang F1. Journal: J Clin Oncol. 2019 Jan 20;37(3):259. doi: 10.1200/JCO.18.00993. Epub 2018 Nov 29. PubMed DOI |
4. | Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. Author: Shuen AY1,2, Lanni S2, Panigrahi GB2, Edwards M2, Yu L2, Campbell BB1,2, Mandel A2, Zhang C2, Zhukova N1,2, Alharbi M3, Bernstein M4, Bowers DC5,6, Carroll S7, Cole KA8, Constantini S9,10, Crooks B4, Dvir R10,11, Farah R12, Hijiya N13, George B14, Laetsch TW5,6, Larouche V15, Lindhorst S16, Luiten RC17, Magimairajan V18, Mason G19, Mason W1,20, Mordechai O21, Mushtaq N22, Nicholas G23, Oren M24, Palma L25, Pedroza LA26,27, Ramdas J28, Samuel D29, Wolfe Schneider K30,31, Seeley A28, Semotiuk K32, Shamvil A33, Sumerauer D34, Toledano H11, Tomboc P35, Wierman M31, Van Damme A36, Lee YY37, Zapotocky M1,2,34, Bouffet E1,2, Durno C2,32, Aronson M32, Gallinger S32,38, Foulkes WD39, Malkin D1,2, Tabori U1,2, Pearson CE1,2. Journal: J Clin Oncol. 2019 Feb 20;37(6):461-470. doi: 10.1200/JCO.18.00474. Epub 2019 Jan 4. PubMed DOI |
5. | Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma. Author: Wang J1, Dong R1, Li K1. Journal: J Clin Oncol. 2019 Mar 20;37(9):754. doi: 10.1200/JCO.18.01385. Epub 2019 Feb 12. PubMed DOI |
6. | Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice? Author: Zhang S1. Journal: J Clin Oncol. 2019 Apr 10;37(11):939. doi: 10.1200/JCO.18.01864. Epub 2019 Feb 27. PubMed DOI |
7. | Reply to Z. McCaw and L-J. Wei. Author: Li J1, Liu Q1, Yang H1, Fu J1. Journal: J Clin Oncol. 2019 Apr 20;37(12):1034. doi: 10.1200/JCO.18.01829. Epub 2019 Mar 6. PubMed DOI |
8. | Clinical Diagnosis Value of Chest X-Ray and Ultrasound in Recurrence in Patients With Favorable-Histology Wilms Tumor. Author: Xie L1, Liu B1, Dong K1. Journal: J Clin Oncol. 2019 May 10;37(14):1264. doi: 10.1200/JCO.18.01886. Epub 2019 Mar 15. PubMed DOI |
9. | ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Author: Shaw AT1, Solomon BJ2, Besse B3, Bauer TM4, Lin CC5, Soo RA6, Riely GJ7, Ou SI8, Clancy JS9, Li S10, Abbattista A11, Thurm H10, Satouchi M12, Camidge DR13, Kao S14, Chiari R15, Gadgeel SM16, Felip E17, Martini JF10. Journal: J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. PubMed DOI |
10. | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Author: Leonard JP1, Trneny M2, Izutsu K3, Fowler NH4, Hong X5, Zhu J6, Zhang H7, Offner F8, Scheliga A9, Nowakowski GS10, Pinto A11, Re F12, Fogliatto LM13, Scheinberg P14, Flinn IW15, Moreira C16, Cabeçadas J17, Liu D18, Kalambakas S18, Fustier P19, Wu C18, Gribben JG20; AUGMENT Trial Investigators. Journal: J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. PubMed DOI |
|
|